Premium
African Americans with Pancreatic Ductal Adenocarcinoma Exhibit Gender Differences in Kaiso Expression
Author(s) -
Mukherjee Angana,
Jones Jacqueline,
Yates Clayton
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.807.2
Subject(s) - cancer research , prostate cancer , pancreatic cancer , epithelial–mesenchymal transition , oncology , cancer , medicine , biology , metastasis
Kaiso, a bi‐modal transcription factor, regulates gene expression and is elevated in breast, prostate, and colon cancers. Depletion of Kaiso in other cancer types leads to a reduction in markers for the epithelial– mesenchymal transition (EMT), however, its clinical implications in pancreatic ductal adenocarcinoma (PDCA) have not been widely explored. PDCA is rarely detected at an early stage but is characterized by rapid progression and invasiveness. Herein, we report the significance of the subcellular localization of Kaiso in PDCAs from African Americans. In the overall patient population, we observed a higher expression of cytoplasmic Kaiso in high‐grade pancreatic tumors compared to low‐grade pancreatic tumors (P = 0.0435). Kaiso expression was higher in the cytoplasm of invasive and metastatic pancreatic cancers (P < 0.0001). In males, cytoplasmic and nuclear expression of Kaiso correlated with cancer grade and lymph node positivity (P = 0.0013; P = 0.0112 and P = 0.0177, respectively). In male and female patients, cytoplasmic Kaiso expression correlated with invasiveness (P = 0.0101). Further, analysis of the largest PDCA dataset available on ONCOMINE shows that with an increase in Kaiso expression, there is an overall increase in Zeb1, which is the inverse for E‐cadherin. Hence, these findings suggest an oncogenic role for Kaiso in the progression of PDCAs, involving the EMT markers, E‐cadherin and Zeb1. Support or Funding Information This work was supported by the Department of Defense Prostate Cancer Research Program (PC120913) [CY], G12 RR03059‐21A1 (NIH/RCMI) [CY], (NIH/NCI) 1 R21 CA188799‐01 [CY] and U54 CA118623 (NIH/NCI) [CY], a pilot project on Pancreatic SPORE 2 P50 CA101955‐11 [CY], Statistical analysis was performed by Tuskegee University Statistical Core.